Oragenics provides Q1 shareholder update on strategic financial progress

Oragenics (OGEN), provided shareholders with an update on its strategic and financial progress for the first quarter of 2025. The Company has made meaningful advancements across regulatory, clinical, financial, and partnership initiatives, further positioning its lead therapeutic candidate, ONP-002, as a first-in-class solution for treating concussion. In the first quarter of 2025, Oragenics achieved several strategic and operational milestones: Industry Engagement & Awareness: Participated in the 12th Annual Brain Health Summit at Leigh Steinberg’s Super Bowl Party 2025, helping raise visibility for traumatic brain injury and ONP-002’s potential therapeutic impact. Strategic Partnership: Established a collaboration with BRAINBox Solutions to combine diagnostic biomarkers with ONP-002’s intranasal delivery system, aiming to transform concussion treatment by enabling faster, more targeted care. Clinical Trial Advancements: Submitted the Investigator’s Brochure for the Phase IIa clinical trial in Australia, marking a key regulatory step. Strengthened Financial Position: Raised approximately $5 million through a combination of dilutive and non-dilutive capital, including approximately $2.6 million via At-the-Market equity financing and approximately $2.25 million through non-dilutive debt funding. Shareholder Communications: Announced that the 2025 Annual Shareholder Meeting will be held on May 2, 2025, with the preliminary proxy filed with the SEC on March 19, 2025.